[Report of six cases of myeloid tumors combined with pyoderma gangrenosum and literature review].

Jianwei Yu, Lo Y, Weijian Xu, Chenxuan Mei, Xinxin Zhou, Lin Ye, Hongyan TongPubMed 2023 · DOI

TL;DR

This paper reports on six cases of myeloid tumors co-occurring with pyoderma gangrenosum (PG), a rare and severe skin condition. The study highlights that PG can be an early indicator of underlying myeloid malignancies, emphasizing the need for hematological evaluation in PG patients. The findings suggest that while corticosteroids are effective for PG, the prognosis is often poor due to the aggressive nature of the associated myeloid tumors.

What Problem Does This Paper Address?

Pyoderma gangrenosum (PG) is a rare, non-infectious neutrophilic dermatosis characterized by rapidly progressing, painful, necrotic ulcers. While PG is known to be associated with various systemic diseases, its link with hematological malignancies, particularly myeloid tumors like myelodysplastic syndromes (MDS) and primary myelofibrosis (PMF), is less frequently reported in domestic literature. This paper addresses the challenge of recognizing this association, understanding its clinical characteristics, and exploring treatment outcomes in a cohort of patients with myeloid tumors and PG. The authors aim to shed light on the diagnostic and prognostic implications of this co-occurrence, which can be crucial for timely intervention and improved patient management.

Methods

The study employed a retrospective case series approach, analyzing six patients diagnosed with myeloid tumors and pyoderma gangrenosum at the First Affiliated Hospital of Zhejiang University between 2014 and the present. The diagnosis of PG was based on established clinical and pathological criteria. For the pathological confirmation of PG, skin biopsies were performed, revealing chronic suppurative inflammation or neutrophilic infiltration. The paper also includes a literature review to contextualize the findings within the broader understanding of PG and its association with hematological malignancies. Treatment strategies, including anti-infectives, corticosteroids, and specific treatments for the underlying myeloid malignancy, were documented and their efficacy assessed.

Datasets

The study utilized a dataset of six patients from the First Affiliated Hospital of Zhejiang University. No new datasets were introduced. The analysis also incorporated data from a review of existing domestic and international literature on myeloid tumors and pyoderma gangrenosum.

Key Insights and Ideas

  • PG as a potential harbinger of myeloid malignancy: The study underscores that PG can be an early manifestation of underlying myeloid tumors, prompting the need for thorough hematological investigations in patients presenting with PG, especially if routine blood counts are abnormal.
  • Clinical presentation overlap: The reported cases demonstrate a wide range of skin lesion distributions and morphologies, consistent with typical PG presentations, but occurring in the context of diagnosed or subsequently discovered myeloid malignancies.
  • Treatment challenges and efficacy: While corticosteroids were found to be effective in achieving remission of PG lesions in most patients, relapses were observed upon dose reduction, highlighting the chronic nature of the condition and the need for careful management.
  • Prognostic implications: The co-occurrence of myeloid tumors with PG appears to be associated with a poorer prognosis, with a higher risk of malignant transformation and increased mortality, as evidenced by the outcomes in the reported cases.
  • Pathological findings: Skin biopsies consistently showed neutrophilic infiltration, a hallmark of PG, but the authors note that clonal detection in neutrophils was not performed in their cases, though literature suggests its potential role in linking PG to underlying myeloid clones.

Key Results

  • Six cases of myeloid tumors combined with pyoderma gangrenosum were reported.
  • The patient cohort included 3 males and 3 females with a median age of 44 years.
  • The associated myeloid malignancies were myelodysplastic syndromes (MDS) in 4 cases and primary myelofibrosis (PMF) in 2 cases.
  • PG preceded the diagnosis of myeloid malignancy in 2 cases, occurred after the hematological diagnosis in 3 cases, and was diagnosed concurrently in 1 case.
  • Skin lesions were widespread, affecting limbs, face, and perianal areas.
  • All patients responded to corticosteroid therapy, with remission achieved within 2-10 days.
  • Three patients remained in remission after gradual corticosteroid tapering, while two experienced mild relapses that improved with dose adjustments.
  • Three patients in the cohort died within a short period due to the progression of their primary hematological disease.

Limitations and Future Work

The authors acknowledge that the study is based on a small sample size (six cases), which limits the generalizability of the findings. They also note that clonal detection in neutrophils was not performed, which could provide further insights into the pathogenesis of PG in the context of myeloid malignancies. Future research should focus on larger, multi-center studies to better understand the epidemiological characteristics, diagnostic criteria, and optimal treatment strategies for this complex co-occurrence. Further investigation into the mechanisms linking myeloid malignancies and PG, including the role of specific cytokines and neutrophil behavior, is also warranted. The paper suggests that effective control of PG may be linked to the successful treatment of the underlying hematological malignancy, a hypothesis that requires further validation.

Summary updated

BibTeX
@inproceedings{yu2023report,
  author = {Jianwei Yu and Lo Y and Weijian Xu and Chenxuan Mei and Xinxin Zhou and Lin Ye and Hongyan Tong},
  title = {{[Report of six cases of myeloid tumors combined with pyoderma gangrenosum and literature review].}},
  booktitle = {PubMed},
  year = {2023},
  doi = {10.3760/cma.j.issn.0253-2727.2023.11.011},
}
Figure